Free Preview
Pre-commercial drug developers don't have traditional fundamentals to analyze, but investors can estimate the likelihood of clinical development. 7investing Lead Advisors Simon Erickson checks in with Maxx Chatsko on his new quest to build accurate, risk-adjusted net present value (rNPV) models for drug developers.